Arrowhead Pharmaceuticals has secured its first U.S. approval with Redemplo, an RNA interference therapy cleared by the FDA for adults with familial chylomicronemia syndrome (FCS). Used alongside dietary management, as reported by BioPharma Dive, Redemplo is administered as a subcutaneous injection once every three months to reduce triglyceride levels in this rare genetic disorder that prevents normal fat breakdown in the bloodstream.
The approval caps a decades-long effort by Arrowhead, a company that helped advance RNAi technology but, until now, lacked a marketed product. Despite a sizeable pipeline and multiple partnerships, Arrowhead had trailed peers like Alnylam in commercial traction and recorded a roughly $600 million net loss last year. Its momentum has accelerated in 2025, however, with investor confidence rising as its delivery platforms demonstrate potential across multiple cell types.
In clinical testing, Redemplo reduced triglycerides by about 70% versus placebo after one year in Phase 3, a result that has fueled optimism among analysts. Jefferies’ Maury Raycroft has argued Redemplo could emerge as the “best treatment” for FCS, citing advantages in efficacy, safety, and convenience relative to Ionis Pharmaceuticals’ Tryngolza, which became the first FDA-approved FCS therapy last year. While head-to-head trials are lacking and cross-study comparisons are imperfect, Ionis’ drug showed a 59% reduction versus placebo and carries a safety warning for hypersensitivity reactions linked to discontinuations—warnings not included in Redemplo’s label. The most common Redemplo side effects were hyperglycemia, headache, nausea, and injection site reactions.
Arrowhead’s pricing strategy could be equally disruptive. Redemplo will launch at a yearly wholesale acquisition cost of $60,000, far below Tryngolza’s $595,000 list price. Executives said they intend to keep a uniform price across future indications, prioritizing long-term market positioning over near-term revenue in FCS, which affects an estimated 6,500 people in the U.S. The larger commercial opportunity lies in severe hypertriglyceridemia, where both companies are advancing programs; Ionis has reported late-stage success, and Arrowhead expects pivotal data next year. Early signs suggest Redemplo could match or surpass its rival in that setting as well.
The competition is playing out in court, too. Ionis has accused Arrowhead of patent infringement, while Arrowhead is seeking a declaration that the patent is invalid or not infringed.
For Arrowhead, Redemplo’s clearance is both scientific validation and a commercial starting line. With a convenient quarterly injection schedule, a favorable safety profile, robust triglyceride lowering, and a strikingly lower price, Redemplo may reshape treatment expectations for FCS and set the stage for broader advances in lipid disorders. U.S. availability is expected by year-end.
